Zymedi is a new drug development company based on protein synthetase and is developing treatments for intractable diseases such as pulmonary arterial hypertension
Investors 1
| Date | Name | Website |
| - | UTC Invest... | utc.co.kr |
Mentions in press and media 1
| Date | Title | Description | Source |
| 08.02.2024 | First in Human Dosed in Clinical Trial of ZMA001 for Treatme... | INCHEON, South Korea, Feb. 8, 2024 /PRNewswire/ -- Zymedi announced today that the first in human do... | en.prnasia... |